Parameter | Belgian cohort | ||
IGP (%) | EGP (%) | ||
Histological type | Adenocarcinoma | 40 (40.4) | 21 (21.2) |
Squamous cell carcinoma | 19 (19.2) | 19 (19.2) | |
P value | 0.14 | ||
Histological grade | Well differentiated | 12 (12.1) | 7 (7.1) |
Moderately differentiated | 32 (32.3) | 26 (26.3) | |
Poorly differentiated | 15 (15.1) | 7 (7.1) | |
P value | 0.5 | ||
T stage | T1 | 9 (9.1) | 7 (7.1) |
T2 | 13 (13.1) | 6 (6.1) | |
T3 | 32 (32.3) | 21 (21.2) | |
T4 | 2 (2.0) | 2 (2.0) | |
Unknown | 3 (3.0) | 4 (4.0) | |
P value | 0.8 | ||
N stage | N0 | 17 (17.2) | 19 (19.2) |
N1 | 32 (32.3) | 11 (11.1) | |
N2 | 2 (2.0) | 1 (1.0) | |
N3 | 1 (1.0) | 0 (0.0) | |
Unknown | 7 (7.1) | 9 (9.1) | |
P value | 0.04 | ||
Treatment | Surgery only | 18 (18.2) | 16 (16.2) |
CT | 26 (26.3) | 16 (16.2) | |
CRT | 15 (15.1) | 8 (8) | |
P value | 0.6 | ||
Lymphovascular embolus | Presence | 25 (25.2) | 2 (2) |
Absence | 21 (21.2) | 16 (16.2) | |
Unknown | 13 (13.1) | 22 (22.2) | |
P value | 0.002 | ||
Perinervous infiltration | Presence | 24 (24.2) | 2 (2) |
Absence | 20 (20.2) | 14 (14.2) | |
Unknown | 15 (15.1) | 24 (24.2) | |
P value | 0.004 |
T stage and N stage concern the cTNM evaluation. Fisher’s exact test was performed using the core package of R.
CRT, chemoradiotherapy; CT, chemotherapy; EGP, expansive growth pattern; IGP, infiltrative growth pattern; OESCC, oesophageal squamous cell carcinoma.